Chronic Lymphocytic Leukemia Stocks List

Related ETFs - A few ETFs which own one or more of the above listed Chronic Lymphocytic Leukemia stocks.

Chronic Lymphocytic Leukemia Stocks Recent News

Date Stock Title
May 2 GMAB Genmab A/S 2024 Q1 - Results - Earnings Call Presentation
May 2 GMAB Genmab reports Q1 results
May 2 GMAB Genmab Announces Financial Results for the First Quarter of 2024
May 2 LGND Novo Nordisk (NVO) Q1 Earnings Beat, GLP-1 Drugs Boost Sales
May 2 TEVA Teva’s 2023 Healthy Future Report Showcases Renewed Sustainability Strategy and Ambitious Targets
May 2 TEVA Q1 2024 Corcept Therapeutics Inc Earnings Call
May 2 BIIB Biogen Reports Progress on Corporate Responsibility Priorities
May 2 EBS Why Aspen Aerogels Shares Are Trading Higher By 26%; Here Are 20 Stocks Moving Premarket
May 2 EBS Emergent BioSolutions gains as results top estimates, co to cut 300 jobs
May 2 EBS Emergent BioSolutions Inc (EBS) (Q1 2024) Earnings Call Transcript Highlights: A Strong Start ...
May 2 TEVA Corcept Therapeutics Inc (CORT) Q1 2024 Earnings Call Transcript Highlights: Strong Growth Amid ...
May 2 EBS PRESS DIGEST- Wall Street Journal - May 2
May 2 EBS Emergent BioSolutions (EBS) Q1 2024 Earnings Call Transcript
May 2 EBS Emergent BioSolutions Inc. (EBS) Q1 2024 Earnings Call Transcript
May 2 EBS Emergent BioSolutions Inc. 2024 Q1 - Results - Earnings Call Presentation
May 1 EBS Emergent BioSolutions Reports Surprising Q1 2024 Earnings, Exceeding Revenue and Net Income ...
May 1 EBS Narcan-Maker Emergent BioSolutions to Cut 300 Jobs, Close Facilities
May 1 EBS Emergent Biosolutions Non-GAAP EPS of $0.59 beats by $1.45, revenue of $300.4M beats by $75.9M
May 1 EBS Emergent BioSolutions Reports First Quarter 2024 Financial Results
May 1 EBS Emergent BioSolutions to lay off about 300 employees
Chronic Lymphocytic Leukemia

Chronic lymphocytic leukemia (CLL) is a type of cancer in which the bone marrow makes too many lymphocytes (a type of white blood cell). Early on there are typically no symptoms. Later non-painful lymph nodes swelling, feeling tired, fever, or weight loss for no clear reason may occur. Enlargement of the spleen and anemia may also occur. It typically worsens gradually.Risk factors include having a family history of the disease. Exposure to Agent Orange and certain insecticides might also be a risk. CLL results in the buildup of B cell lymphocytes in the bone marrow, lymph nodes, and blood. These cells do not function well and crowd out healthy blood cells. CLL is divided into two main types: those with a mutated IGHV gene and those without. Diagnosis is typically based on blood tests finding high numbers of mature lymphocytes and smudge cells.Management of early disease is generally with watchful waiting. Infections should more readily be treated with antibiotics. In those with significant symptoms, chemotherapy or immunotherapy may be used. The medications fludarabine, cyclophosphamide, and rituximab are typically the initial treatment in those who are otherwise healthy.CLL affected about 904,000 people globally in 2015 and resulted in 60,700 deaths. The disease most commonly occurs in people over the age of 50. Males are affected more often than females. It is much less common in people from Asia. Five-year survival following diagnosis is approximately 83% in the United States. It represents less than 1% of deaths from cancer.

Browse All Tags